Payment overview · 2025
General Payments
$197.90
11 reported records · 4 companies
Healthcare provider profile · identity verified
Brett A Smith, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · SODA SPRINGS, ID · NPI 1932180668
Verified facts
What the public records show
CMS Open Payments records show Brett A Smith, PA-C received $197.90 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 55.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $108.90 | 55.0% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.14 | 26.4% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $23.08 | 11.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.78 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $197.90 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $69.86 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.04 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.04 | 2 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 579 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 394 | 70 |
| Omeprazole | Omeprazole | 351 | 64 |
| Lisinopril | Lisinopril | 329 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 313 | 49 |
| Gabapentin | Gabapentin | 244 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 40 |
| Potassium Chloride | Potassium Chloride | 221 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 210 | 35 |
| Metformin Hcl | Metformin Hcl | 208 | 41 |
| Carvedilol | Carvedilol | 180 | 29 |
| Montelukast Sodium | Montelukast Sodium | 174 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 30 |
| Trazodone Hcl | Trazodone Hcl | 153 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 30 |
| Simvastatin | Simvastatin | 143 | 26 |
| Allopurinol | Allopurinol | 126 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 26 |
| Furosemide | Furosemide | 113 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 109 | 21 |
| Tramadol Hcl | Tramadol Hcl | 108 | 24 |
| Lorazepam | Lorazepam | 107 | 18 |
| Glimepiride | Glimepiride | 104 | 20 |
| Famotidine | Famotidine | 99 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 23 |
| Meloxicam | Meloxicam | 99 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 12 |
| Bupropion Xl | Bupropion Hcl | 81 | 13 |
| Spironolactone | Spironolactone | 81 | 13 |
| Alprazolam | Alprazolam | 76 | 15 |
| Clonazepam | Clonazepam | 75 | 11 |
| Sertraline Hcl | Sertraline Hcl | 72 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | suppressed |
| Prednisone | Prednisone | 62 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 13 |
| Methylprednisolone | Methylprednisolone | 60 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 52 | suppressed |
| Pregabalin | Pregabalin | 51 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 48 | suppressed |
| Baclofen | Baclofen | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | suppressed |
| Verapamil Er | Verapamil Hcl | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Ozempic | Semaglutide | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 35 |
| Celecoxib | Celecoxib | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 23 |
| Finasteride | Finasteride | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 23 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 22 |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 14 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Estarylla | Norgestimate-Ethinyl Estradiol | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Clonidine | Clonidine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $197.90 · 11 records | ABBVIE INC. | GATTEX, GVOKE HYPOPEN, Ozempic, QULIPTA, UBRELVY, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error